GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma

CONCLUSIONS: Our experimental data indicate the feasibility of CAR.GD2 T-cell therapy. A phase I/II clinical trial will be conducted to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.PMID:38551501 | DOI:10.1158/1078-0432.CCR-23-1880

Source: Clinical Cancer Research - March 29, 2024 Category: Cancer & Oncology Authors: Roselia Ciccone Concetta Quintarelli Antonio Camera Michele Pezzella Simona Caruso Simona Manni Alessio Ottaviani Marika Guercio Francesca Del Bufalo Maria Cecilia Quadraccia Domenico Orlando Stefano Di Cecca Matilde Sinibaldi Mariasole Aurigemma Laura Ia Source Type: research